Welch Group LLC lifted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 14.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,349 shares of the medical research company’s stock after purchasing an additional 172 shares during the period. Welch Group LLC’s holdings in Amgen were worth $256,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of AMGN. Oregon Public Employees Retirement Fund boosted its holdings in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares during the last quarter. Norges Bank acquired a new position in shares of Amgen during the 4th quarter worth approximately $1,283,248,000. BlackRock Inc. boosted its holdings in shares of Amgen by 2.0% during the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after purchasing an additional 906,568 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of Amgen by 536.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 524,376 shares of the medical research company’s stock valued at $102,080,000 after buying an additional 441,995 shares during the period. Institutional investors and hedge funds own 80.65% of the company’s stock.
Several analysts have recently commented on AMGN shares. Mizuho set a $208.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Friday, March 22nd. Goldman Sachs Group reaffirmed a “buy” rating and set a $232.00 price target on shares of Amgen in a research report on Thursday, January 17th. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 29th. Oppenheimer set a $224.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Sunday, January 27th. Finally, Cowen reaffirmed a “buy” rating and set a $234.00 price target on shares of Amgen in a research report on Tuesday, February 26th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. Amgen presently has a consensus rating of “Hold” and an average price target of $208.84.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.45 by $0.11. The company had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.47 earnings per share. Analysts predict that Amgen, Inc. will post 13.93 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the sale, the director now owns 14,988 shares of the company’s stock, valued at $2,830,933.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 6,000 shares of company stock worth $1,115,580. 0.25% of the stock is owned by corporate insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Cost of Debt
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.